SCHEDULE 13G/A: Hudson Bay Capital Management LP Discloses 4.99% Passive Stake in Aptevo Therapeutics Inc.
Beneficial Ownership Disclosure
Hudson Bay Capital Management LP and Sander Gerber have reported a 4.99% beneficial ownership stake in Aptevo Therapeutics Inc., primarily through shares issuable upon warrant exercise, as of December 31, 2024.
Summary
- Hudson Bay Capital Management LP and Mr. Sander Gerber reported beneficial ownership of 76,598 shares of Aptevo Therapeutics Inc. common stock.
- This ownership represents 4.99% of the company's outstanding common stock.
- The reported shares include 76,598 shares issuable upon the exercise of warrants.
- The percentage is calculated based on 1,458,443 shares of common stock outstanding as of December 16, 2024, as reported in the company's Form S-3.
- The filing indicates a passive investment, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership. It does not contain positive or negative operational or financial news about the issuer, Aptevo Therapeutics Inc., nor does it indicate any intent to influence control.
Positives
- The filing indicates a passive investment by a notable investment manager, Hudson Bay Capital Management LP, which could be viewed as a vote of confidence in Aptevo Therapeutics Inc.'s long-term prospects.
- The stake is below the 5% threshold, reinforcing that the investment is not intended to influence control of the issuer, which can reduce concerns about potential activist interventions.
Negatives
- The document itself does not contain negative financial or operational information about Aptevo Therapeutics Inc.; it is purely an ownership disclosure.
Risks
- The document does not explicitly state risks related to Aptevo Therapeutics Inc.'s operations or financial health; it is an ownership disclosure.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of a passive investment stake by an investment firm in a publicly traded company. It does not provide broader industry trends or competitive analysis, focusing solely on the ownership structure.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, albeit passive, ownership stake by an institutional investor, which can offer insights into institutional interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-12-16 | Date as of which 1,458,443 shares of common stock were reported outstanding for percentage calculation. |
| 2024-12-20 | Date Aptevo Therapeutics Inc. filed its Registration Statement on Form S-3, reporting outstanding shares. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership stake). |
| 2025-02-10 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Aptevo Therapeutics Inc., Hudson Bay Capital Management LP, Sander Gerber, Schedule 13G, beneficial ownership, common stock, warrants, investment management, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.